Palo Alto, California, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Rayont Inc. ("Rayont" or the "Company") (OTC PINK: RAYT), an international personalized natural healthcare company, today reported financial results for the three-month ended September 30, 2022.
Business Highlights Within the Three-Month ended September 30, 2022:
Ms. Marshini Moodley, CEO and CFO, said, "We recorded an increase in both the revenue and gross profit for the period ended September 30, 2022 compared to same period last year, mainly due to acquisition of the business of No More Knots Pty Ltd, No More Knots (Newmarket) Pty Ltd, No More Knots (Taringa) Pty Ltd, Ipswich Massage Pty Ltd and Tugun Compounding Pharmacy Pty Ltd.
Three-month Ending September 30, 2022, Financial Results:
| | | Three Months Ended September 30, | |
| | | 2022 | | | 2021 | |
| Revenues | | $ | 1,368,677 | | | $ | 687,523 | |
| Gross Profit | | $ | 798,262 | | | $ | 358,173 | |
Improved Balance Sheet Results
| | | | September 30,
2022 | | | | June 30,
2022 | |
| Cash | | $ | 28,921 | | | $ | 185,782 | |
| Total Assets | | $ | 8,980,404 | | | $ | 14,193,235 | |
| Total Liabilities | | $ | 2,678,754 | | | $ | 9,099,623 | |
| Total Stockholders' Equity | | $ | 6,301,650 | | | $ | 5,093,612 | |
Marshini Moodley added, "Our quarterly performance reflecting decreased total asset portfolio and total liabilities mainly as result of the sale of three subsidiaries of the group that included mostly the land, properties and loans related with those properties. Due to that, the working capital is improved as there was a working capital deficit of $83,884 on June 30, 2022 and working capital of $1,730,581 on September 30, 2022. Our cash reserves have decreased due to capital investments and servicing loan interest received to cover different investments done from the Company during the quarter".
Strategies for Growth
During this financial year we continue to undertake several key activities aimed to improve the overall performance of Rayont Inc namely:
- Continue to consolidate the operations of Prema Life with that of Tugun Compounding Pharmacy to drive cost reduction and efficiencies across both operations.
- Launch Health Script telehealth platform for naturopaths globally with key markets focus Australia and the USA.
- Continue with smaller acquisitions that can contribute to revenue growth and synergies across the group. We expect that the acquisitions made to date will contribute to significant revenue and profit growth this financial year.
These activities are being worked on and we will communicate their completions as we achieve them.
Disclosure Regarding the Financial Reports Provided in the Form 10-Q
The auditor's review for current version of the Form 10Q has not been completed due to the fact that the valuation report for the acquisition of the business of Ipswich Massage Pty Ltd, Prema Life Pty Ltd and Tugun Compounding Pharmacy Pty Ltd by an independent expert that not been completed. The company is in process of procuring these reports.
Once the auditor's review is ready, the Company will file an amendment to its Form 10-Q.
About Rayont Inc.
Rayont, Inc. (RAYT) is a public traded company incorporated in Nevada, USA since its inception in 2011. In 2018, the Company repositioned itself to focus on personalized natural healthcare industry.
Rayont uses scientific tools such as DNA, microbiome, iridology and other tests to personalize diagnoses, prescription and treatments of natural complementary and alternative medicine products, services and treatments to our patients in the markets we operate.
For further information, please visit
SAFE HARBOR
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933, are subject to Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbors created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and other results and further events could differ materially from those anticipated in such statements. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements.
Company Contact:
Investor Relations
ir@rayont.com
Palo Alto, California, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Rayont Inc. ("Rayont" or the "Company") (OTC PINK: RAYT), an international personalized natural healthcare company, today reported financial results for the three-month ended September 30, 2022.
加利福尼亚州帕洛阿尔托，2023年1月17日(Global Newswire)--国际个性化自然保健公司Rayont Inc.(“Rayont”or“Company”)(场外交易代码：RAYT)今天公布了截至2022年9月30日的三个月的财务业绩。
Business Highlights Within the Three-Month ended September 30, 2022:
中的业务亮点THREE-截至月底九月 30, 2022:
Ms. Marshini Moodley, CEO and CFO, said, "We recorded an increase in both the revenue and gross profit for the period ended September 30, 2022 compared to same period last year, mainly due to acquisition of the business of No More Knots Pty Ltd, No More Knots (Newmarket) Pty Ltd, No More Knots (Taringa) Pty Ltd, Ipswich Massage Pty Ltd and Tugun Compounding Pharmacy Pty Ltd.
首席执行官兼首席财务官Marshini Moodley女士表示：“与去年同期相比，我们在截至2022年9月30日止期间的收入和毛利均录得增长，这主要是由于收购了No More Knots Pty Ltd、No Knots(Newmarket)Pty Ltd、No Knots(Taringa)Pty Ltd、Ipswich Masage Pty Ltd和Tugan Componding Pharmacy Pty Ltd的业务。
Three-month Ending September 30, 2022, Financial Results:
THREE-月末九月 30, 2022,财务业绩：
| |
|
Three Months Ended September 30,
|
|
| |
|
2022
|
|
|
2021
|
|
| Revenues |
|
$ |
1,368,677 |
|
|
$ |
687,523 |
|
| Gross Profit |
|
$ |
798,262 |
|
|
$ |
358,173 |
|
| |
|
THREE截至的月份九月 30,
|
|
| |
|
2022
|
|
|
2021
|
|
| 收入 |
|
$ |
1,368,677 |
|
|
$ |
687,523 |
|
| 毛利 |
|
$ |
798,262 |
|
|
$ |
358,173 |
|
Improved Balance Sheet Results
| |
|
|
September 30,
2022
|
|
|
|
June 30,
2022
|
|
| Cash |
|
$ |
28,921 |
|
|
$ |
185,782 |
|
| Total Assets |
|
$ |
8,980,404 |
|
|
$ |
14,193,235 |
|
| Total Liabilities |
|
$ |
2,678,754 |
|
|
$ |
9,099,623 |
|
| Total Stockholders' Equity |
|
$ |
6,301,650 |
|
|
$ |
5,093,612 |
|
| |
|
|
九月 30,
2022
|
|
|
|
6月30日，
2022
|
|
| 现金 |
|
$ |
28,921 |
|
|
$ |
185,782 |
|
| 总资产 |
|
$ |
8,980,404 |
|
|
$ |
14,193,235 |
|
| 总负债 |
|
$ |
2,678,754 |
|
|
$ |
9,099,623 |
|
| 股东权益总额 |
|
$ |
6,301,650 |
|
|
$ |
5,093,612 |
|
Marshini Moodley added, "Our quarterly performance reflecting decreased total asset portfolio and total liabilities mainly as result of the sale of three subsidiaries of the group that included mostly the land, properties and loans related with those properties. Due to that, the working capital is improved as there was a working capital deficit of $83,884 on June 30, 2022 and working capital of $1,730,581 on September 30, 2022. Our cash reserves have decreased due to capital investments and servicing loan interest received to cover different investments done from the Company during the quarter".
Marshini Moodley补充说：我们的季度业绩反映了总资产组合和总负债的减少，这主要是由于出售了集团的三家子公司，其中主要包括土地、物业和与该等物业相关的贷款。因此，营运资本有所改善，因为存在营运资本赤字$83,8842022年6月30日和营运资金$1,730,5812022年9月30日。我们的现金储备有所减少，原因是资本投资和为支付公司在本季度进行的不同投资而收到的还本付息贷款“。
During this financial year we continue to undertake several key activities aimed to improve the overall performance of Rayont Inc namely:
在本财政年度，我们继续开展旨在改善Rayont Inc.整体业绩的几项关键活动，即：
- Continue to consolidate the operations of Prema Life with that of Tugun Compounding Pharmacy to drive cost reduction and efficiencies across both operations.
- Launch Health Script telehealth platform for naturopaths globally with key markets focus Australia and the USA.
- Continue with smaller acquisitions that can contribute to revenue growth and synergies across the group. We expect that the acquisitions made to date will contribute to significant revenue and profit growth this financial year.
- 继续整合普莱玛人寿和图贡复方药房的业务，以推动两项业务的成本降低和效率提高。
- 为全球主要市场澳大利亚和美国推出面向自然疗法的Health脚本远程健康平台。
- 继续进行规模较小的收购，以促进整个集团的收入增长和协同效应。我们预计，到目前为止进行的收购将为本财年的收入和利润增长做出重大贡献。
These activities are being worked on and we will communicate their completions as we achieve them.
这些活动正在进行中，我们将在实现它们时通报它们的完成情况。
Disclosure Regarding the Financial Reports Provided in the Form 10-Q
披露R关注美国的F财务状况R报告前提是在表格10-Q中
The auditor's review for current version of the Form 10Q has not been completed due to the fact that the valuation report for the acquisition of the business of Ipswich Massage Pty Ltd, Prema Life Pty Ltd and Tugun Compounding Pharmacy Pty Ltd by an independent expert that not been completed. The company is in process of procuring these reports.
核数师对当前版本的表格10Q的审核尚未完成，原因是独立专家收购Ipswich按摩器有限公司、Prema Life Pty有限公司和Tugan Componding Pharmacy Pty Ltd的业务的估值报告尚未完成。该公司正在采购这些报告。
Once the auditor's review is ready, the Company will file an amendment to its Form 10-Q.
一旦审计师的审查准备就绪，公司将提交对其10-Q表格的修正。
Rayont, Inc. (RAYT) is a public traded company incorporated in Nevada, USA since its inception in 2011. In 2018, the Company repositioned itself to focus on personalized natural healthcare industry.
Rayont，Inc.(RAYT)是一家上市公司，自2011年成立以来一直在美国内华达州成立。2018年，公司重新定位，专注于个性化的自然保健行业。
Rayont uses scientific tools such as DNA, microbiome, iridology and other tests to personalize diagnoses, prescription and treatments of natural complementary and alternative medicine products, services and treatments to our patients in the markets we operate.
Rayont使用DNA、微生物组、虹膜学和其他测试等科学工具，为我们运营的市场中的患者提供个性化的天然补充和替代医学产品、服务和治疗的诊断、处方和治疗。
For further information, please visit
Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933, are subject to Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbors created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and other results and further events could differ materially from those anticipated in such statements. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements.
本新闻稿中的某些陈述可能包含1933年《证券法》第175条规定的前瞻性信息，受1934年《证券交易法》第3b-6条的约束，并受这些规定所创造的安全港的约束。本新闻稿中包含的除事实陈述外的所有陈述，包括但不限于有关公司潜在的未来计划和目标的陈述，均为前瞻性陈述，涉及风险和不确定性。不能保证这样的陈述将被证明是准确的，其他结果和进一步的事件可能与这种陈述中预期的大不相同。未来的事件和实际结果可能与前瞻性陈述中陈述的、预期的或潜在的大不相同。
Company Contact:
Investor Relations
ir@rayont.com
公司联系人：
投资者关系
邮箱：ir@rayont.com
